

# Reactive Oxygen Species Suppress Cardiac Na<sub>v</sub>1.5 Expression through Foxo1

Weike Mao<sup>1,9</sup>, Tao You<sup>1,3,9</sup>, Bo Ye<sup>1</sup>, Xiang Li<sup>1</sup>, Henry H. Dong<sup>4</sup>, Joseph A. Hill<sup>5</sup>, Faqian Li<sup>1</sup>, Haodong Xu<sup>1,2\*</sup>

**1** Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States of America, **2** Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York, United States of America, **3** Division of Cardiology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China, **4** Division of Immunogenetics, Rangoes Research Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States of America, **5** Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

## Abstract

Na<sub>v</sub>1.5 is a cardiac voltage-gated Na<sup>+</sup> channel  $\alpha$ subunit and is encoded by the *SCN5a* gene. The activity of this channel determines cardiac depolarization and electrical conduction. Channel defects, including mutations and decrease of channel protein levels, have been linked to the development of cardiac arrhythmias. The molecular mechanisms underlying the regulation of Na<sub>v</sub>1.5 expression are largely unknown. Forkhead box O (Foxo) proteins are transcriptional factors that bind the consensus DNA sequences in their target gene promoters and regulate the expression of these genes. Comparative analysis revealed conserved DNA sequences, 5'-CAAACA-3' (insulin responsive element, IRE), in rat, mouse and human *SCN5a* promoters with the latter two containing two overlapping Foxo protein binding IREs, 5'-CAAACAACA-3'. This finding led us to hypothesize that Foxo1 regulates Na<sub>v</sub>1.5 expression by directly binding the *SCN5a* promoter and affecting its transcriptional activity. In the present study, we determined whether Foxo1 regulates Na<sub>v</sub>1.5 expression at the transcriptional level and also defined the role of Foxo1 in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-mediated Na<sub>v</sub>1.5 suppression in HL-1 cardiomyocytes using chromatin immunoprecipitation (ChIP), constitutively nuclear Foxo1 expression, and RNAi Foxo1 knockdown as well as whole cell voltage-clamp recordings. ChIP with anti-Foxo1 antibody and follow-up semi-quantitative PCR with primers flanking Foxo1 binding sites in the proximal *SCN5a* promoter region clearly demonstrated enrichment of DNA, confirming Foxo1 recruitment to this consensus sequence. Foxo1 mutant (T24A/S319A-GFP, Foxo1-AA-GFP) was retained in nuclei, leading to a decrease of Na<sub>v</sub>1.5 expression and Na<sup>+</sup> current, while silencing of Foxo1 expression by RNAi resulted in the augmentation of Na<sub>v</sub>1.5 expression. H<sub>2</sub>O<sub>2</sub> significantly reduced Na<sub>v</sub>1.5 expression by promoting Foxo1 nuclear localization and this reduction was prevented by RNAi silencing Foxo1 expression. These studies indicate that Foxo1 negatively regulates Na<sub>v</sub>1.5 expression in cardiomyocytes and reactive oxygen species suppress Na<sub>v</sub>1.5 expression through Foxo1.

**Citation:** Mao W, You T, Ye B, Li X, Dong HH, et al. (2012) Reactive Oxygen Species Suppress Cardiac Na<sub>v</sub>1.5 Expression through Foxo1. PLoS ONE 7(2): e32738. doi:10.1371/journal.pone.0032738

**Editor:** Rossella Rota, Ospedale Pediatrico Bambino Gesù, Italy

**Received:** November 1, 2011; **Accepted:** January 30, 2012; **Published:** February 29, 2012

**Copyright:** © 2012 Mao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** HX is supported by grants from National Institute of Health (NIH) (K08HL088127) and American Heart Association (AHA) (12GRNT9690003); JAH is supported by grants from NIH (HL-075173, HL-080144 and HL-090842), AHA (0640084N), AHA-Jon Holden DeHaan Foundation (0970518N) and American Diabetes Association (7-08-MN-21); HHD is supported by grants from NIH (DK066301 and DK087764); FL is supported by grant from AHA and the Lawrence J. and Florence A. DeGeorge Charitable Trust (10GRNT4460014). The funders had no role in study design, data collect and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: Haodong\_Xu@URMC.Rochester.edu

These authors contributed equally to this work.

Current address: Department of Anesthesiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China

## Introduction

Alterations of ion channel activity play an important role in the development of cardiac arrhythmias. Na<sub>v</sub>1.5 encoded by the *SCN5a* gene is  $\alpha$  subunit of the voltage-gated cardiac Na<sup>+</sup> channel, and this channel activity determines cardiac excitability and conduction. Reactive oxygen species (ROS) are generated during myocardial infarction [1–4] and contribute to the development of life-threatening ventricular arrhythmias [5,6]. It has been shown that alteration of cardiac Na<sup>+</sup> channel activity immediately following ROS challenge requires activation of Ca<sup>2+</sup>-dependent calmodulin II kinase (CaMKII) [7]. CaMKII regulates Na<sup>+</sup> channel gating by phosphorylating Na<sub>v</sub>1.5 to increase late Na<sup>+</sup> current, leading to the prolongation of the action potential

duration and development of early afterdepolarization [8]. H<sub>2</sub>O<sub>2</sub>-chronically mediated downregulation of Na<sup>+</sup> channel activity requires activation of NF- $\kappa$ B to decrease Na<sub>v</sub>1.5 expression by inhibiting *SCN5a* promoter activity [9]. Mutation of the NF- $\kappa$ B binding site in the *SCN5a* promoter eliminates 42.3% decrease of this promoter activity by H<sub>2</sub>O<sub>2</sub> in H9C2 myoblasts [9]. These findings indirectly support the notion that other signaling pathways are also significantly involved in the regulation of Na<sub>v</sub>1.5 expression.

Foxo transcription factors form a subclass of the large family of Forkhead proteins characterized by the presence of a “winged-helix” DNA-binding domain called Forkhead box O, which gave the name Foxo proteins to the family [10]. Post-translational modifications such as phosphorylation, acetylation and methyl-

tion affect Foxo subcellular localization and transcriptional activity [11–13]. Foxo proteins harbor conserved threonine and serines that can be phosphorylated by different kinases, leading to their nuclear retention or exclusion [11]. Akt/protein kinase B (PKB) [14,15], serum and glucocorticoid-induced kinase 1 (SGK1) [16], cyclin-dependent kinase 2 (CDK2) [17] and I $\kappa$ B kinase (IKK) [18] phosphorylate Foxo proteins, resulting in their nuclear exclusion while c-Jun-N-terminal kinase (JNK) [19] and mammalian sterile 20-like kinase 1 (MST1) [20] phosphorylate Foxo proteins, causing their nuclear retention. Foxo proteins also contain acetylated lysines that can be deacetylated by a NAD-dependent histone deacetylase, silent mating type information regulation 2 homolog (Sirt1), leading to their nuclear retention [12]. Protein arginine methyltransferase 1 (PRMT1) methylates Foxo1 primarily at Arg248 and Arg250 within the consensus Akt phosphorylation motif. These methylations directly abrogate Akt-induced phosphorylation of Foxo1 at Ser253, which in turn results in increased Foxo1 nuclear localization [13]. Accumulating evidence suggests that Foxo1, 3 and 4 are expressed in the heart and they are critical in maintaining cardiac function and mediating cardiac stresses. In the heart, the Foxo family is believed to be involved in diverse activities, including response to oxidative stress [21–23], regulation of metabolism [24], modulation of KATP channels [25], promotion of autophagy [26], cell cycle control [27,28], and commitment to apoptosis [29]. In the nucleus, Foxo proteins target a conserved DNA binding sequence, 5'-GTAAA(C/T)A-3' [30] or insulin response element (IRE), 5'-CAAAA(C/T)A-3' [30–32] in the promoters of their target genes to affect these gene expression. The end result of Foxo transcriptional activity is generally associated with counteracting oxidative stress and promoting cell cycle arrest and apoptosis [11]. Silico promoter analysis on a list of 354 of the most differentially expressed genes in the thymocyte lineage predicted that the promoter of *SCN5a* has Foxo binding elements [33].

In this study, we tested the hypothesis that H<sub>2</sub>O<sub>2</sub> suppressing Nav1.5 requires the Foxo1 signaling pathway. Our results showed that Foxo1 negatively regulated Nav1.5 expression by directly binding the *SCN5a* promoter, and H<sub>2</sub>O<sub>2</sub>-mediated inhibition of Nav1.5 expression required Foxo1.

## Materials and Methods

### Ethics

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the University Committee on Animal Resources (UCAR) of University of Rochester Medical Center (UCAR # 2007-060).

### Cell Culture

HeLa cells (obtained from American Type Culture Collection) were maintained in 10 cm plates containing Dulbecco's modified Eagle's medium (high glucose) and 10% fetal bovine serum with 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin. A cardiomyocyte cell line, designated HL-1, from the AT-1 mouse atrial cardiomyocyte tumor lineage, was kindly provided by Dr. William C. Claycomb at Louisiana State University Health Sciences Center, New Orleans, USA. These cells were cultured as described previously [34]. The cells were cultured in Claycomb medium (JRH Biosciences, KS) supplemented with 10% fetal bovine serum (JRH Biosciences, KS), 2 mM L-glutamine, 100  $\mu$ M norepinephrine, 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin in 10 cm plates pre-coated with fibronectin (BD Biosciences, PA). The

medium was changed every 24–48 h. Mouse ventricular myocytes isolated from 10 week old FVB mice as previously described [35] were directly subjected to a chromatin immunoprecipitation (ChIP) assay.

### Bioinformatics

The *SCN5a* genomic promoter sequences from mouse, rat, and human were downloaded from the University of California Santa Cruz genome browser [36] and comparative genomic analysis was done with the visualization tools for alignments (VISTA) algorithm (available from the VISTA web site). The Foxo protein binding sequences were compared.

### Transfection and Luciferase Assays

Lipofectamine<sup>TM</sup> and plus<sup>TM</sup> reagents (Invitrogen) were used to transfect *SCN5a* reporters (*SCN5a* promoter-Luc plasmid [37] was generously provided by Dr. Hideko Kasahara in University of Florida College of Medicine, Florida, USA) and *Foxo1* in the HeLa cells. Cells were seeded in 24-well plates and grown to 90% confluence. Transfections were performed according to the manufacturer's instructions. A *Renilla* reporter gene (Promega) was included as an internal control. Cell lysates were prepared for the luciferase assay 24 hours after transfection as described by the manufacturer (Promega). Data were analyzed and expressed as the normalized-fold changes over controls.

### RT-PCR

Total RNA was extracted from HL-1 and HeLa cells by RNeasy Mini kit (QIAGEN) and reversely transcribed to cDNA with a high capacity cDNA reverse transcription kit (AB Applied Biosystems). Semi-quantitative PCR was conducted to measure mRNA expression levels across different experimental conditions as indicated under "Results". The primers used to amplify mouse(m) Nav1.5, m $\beta$ -actin, human(h) GAPDH, mGAPDH, hFoxo1, and mTR4 were summarized in table 1.

### Western Blotting

HL-1 cells were rinsed with phosphate-buffered saline (PBS) twice, and protein was extracted in cold cell lysis buffer (Cell Signaling). Protein concentration was determined by a detergent-compatible protein assay (Bio-Rad). Equal amounts of protein were resolved by SDS-PAGE, transferred onto nitrocellulose membranes, blocked with 5% non-fat milk for 1 hour, and then incubated with the indicated primary antibody overnight at 4°C. After 1 hour incubation with the appropriate secondary antibody, specific signals were revealed by enhanced chemiluminescence reagent (Pierce). The primary antibodies used were as follows: rabbit anti-Foxo1 polyclonal (Cell Signaling, 1:1000), rabbit anti-Nav1.5 polyclonal (Alomone Labs, 1:500), rabbit anti-GAPDH polyclonal (Millipore, 1:4000), and mouse anti-tubulin monoclonal (Sigma, 1:5000).

### Fluorescence and Confocal Microscopy

HL-1 cells were dispersed on the glass in the center of the 32 mm dishes and grown to 80% confluence. HL-1 cells expressing GFP and Foxo1-GFP were fixed with 4% paraformaldehyde. Nuclear profiles were revealed with a brief incubation in DAPI (Molecular Probes) prior to microscopic observation. Fluorescence was visualized with an inverted Olympus IX81 fluorescence confocal microscope and photographed for direct import into Image J. All images were processed in an identical manner to faithfully capture the real time images of each sample.

**Table 1.** Summary of primers for RT-PCR.

	Forward Primer	Reverse Primer
m1Nav1.5	5'-ACAGGCCTCAAAAAGTCCAGA-3'	5'-GGGTCGTGTGCCATGAACACA-3'
m2Nav1.5	5'-CAGGTCGGAAACTTGGTCTTAC-3'	5'-GAAGATGATGAAAGTCTCGAACCA-3'
m $\beta$ -actin	5'-AGATGTGGATCAGCAG-3'	5'-GCGCAAGTTAGTTTTGTCA-3'
hGAPDH	5'-ACGGATTGGCTGATTGGG-3'	5'-CGCTCTGGAAGATGGTGAT-3'
mGAPDH	5'-TGAACGGATTGGCCGTATTGGG-3'	5'-TCTTCTGGGTGGCAGTGATGGCAT-3'
hFoxo1	5'-AACCTGTCTACGCCGACCTCA-3'	5'-GCTCGGCTTCGGCTCTTAGCAA-3'
mTR4	5'-GTAGCCTCACCTCAGCGCATTCA-3'	5'-GCGGTTACGGTGGTCTTGTG-3'

Note: m, mouse; h, human.

doi:10.1371/journal.pone.0032738.t001

## Adenovirus Vectors

The adenoviral vectors used were as follows: Adv-CMV-FoxO1-AA-GFP expressing constitutively nuclear FoxO1-AA-GFP and Adv-CMV-GFP expressing GFP. Adv-FoxO1-RNAi vector was constructed based on the Block-iT Adenoviral RNAi Expression System (Invitrogen). This FoxO1-RNAi vector encodes a 19-bp DNA (5'-CGCCCCAGGTGGTGGAGAC-3') that is complementary to the Foxo1 mRNA sequence (10–29 nt) under the control of the mouse U6 promoter. Likewise, a control adenovirus containing the scrambled RNAi (5'-GGACTCGGGC-CACCGGGTA-3') (Adv-scramble-RNAi) under the control of mouse U6 promoter was constructed.

## ChIP Assay

ChIP was used to study the interaction between Foxo1 and *SCN5a* promoter DNA in HL-1 cells, as previously described [38]. Approximately  $1 \times 10^7$  HL-1 cells were subjected to the ChIP assay using anti-Foxo1 antibody or rabbit control IgG as a control and the ChIP assay kit (Upstate Biotechnology), as previous described [38]. The immunoprecipitates were analyzed by immunoblot analysis using goat anti-Foxo1 (FKHR-C20; Santa Cruz Biotechnology Inc.), and by PCR assay to detect coimmunoprecipitated DNA using two pairs of *SCN5a* promoter-specific primers (forward 5'-TGGTACATACCGTTTCAGGAC-3' and reverse 5'-GCA-CACACACTCACACATAC-3'; forward 5'-TGGTACATACCGTTTCAGGAC-3' and reverse 5'-ACGCATGCTCAGC-CACACA-3') that flank the consensus Foxo1 binding sites (−1484 to −1473 nt) in the mouse *SCN5a* promoter and a pair of primers (forward 5'-GCCTCATTCGTTGCAGTGTGCC-3' and reverse 5'-GCCAGTGCCTTGTGTGGACTCT-3') that flanked the DNA sequence (−4453 to −4686) lacking Foxo1 binding site as a control.

## Whole-cell Voltage Clamp Recording

Na<sup>+</sup> currents were recorded from HL-cells using whole-cell patch-clamp techniques at room temperature (22–24°C). The bath solution for recording membrane currents contained (in mM) 145 NaCl, 4.5 CsCl, 1.5 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 5 HEPES, 5 glucose, 0.1 CdCl<sub>2</sub> (pH 7.35 with CsOH); the pipette solution contained (in mM) 10 NaF, 110 CsF, 20 CsCl, 10 EGTA, and 10 HEPES (pH 7.35 with CsOH). Electrode resistance ranged from 2.0 to 3.0 M $\Omega$ . Data acquisition was carried out using an Axopatch 200B amplifier and pClampex 9.6 software (Axon Instruments Inc., Foster, CA). Currents were acquired at 20–50 kHz (Digidata 1200 A/D converter; Axon Instruments Inc.) and low-pass-filtered at 5 kHz, and stored on a computer. In all recordings, 80% of the series resistance was compensated. Data analysis was accom-

plished by using pClampfit 9.6 software (Axon Instruments Inc., Foster City, CA).

## Statistical Analysis

All values are expressed as Mean  $\pm$  SEM. Data from experimental groups were compared by student's t-test or ANOVA one way analysis. A value of  $p < 0.05$  was considered statistically significant.

## Results

### The Proximal Region of *SCN5a* Promoter Contains Foxo1 Responsive Elements


Silico promoter analysis on a list of 354 of the most differentially expressed genes in the thymocyte lineage has revealed putative direct targets that are transcriptionally regulated by Foxo proteins in thymocytes, and that *SCN5a* transcription is upregulated by Foxos deletion [33]. These findings suggest that transcription of *SCN5a* may be directly regulated by Foxos in cardiomyocytes. Analysis of the *SCN5a* promoter region showed a highly conserved DNA sequence (5'-CAAAACA-3') as IRE in humans and rodents such as mouse and rat. The mouse and human *SCN5a* promoter regions harbor two overlapping Foxo1 binding IREs, 5'-CAAAACAAAACA-3' (Fig. 1A).

### Foxo1 directly binds *SCN5a* promoter

To confirm the association of Foxo1 with the *SCN5a* promoter region including IREs, a ChIP assay was carried out in HL-1 cells and mouse ventricular myocytes, and it unveiled a clear enrichment of DNA amplified by PCR with two sets of primer pairs flanking Foxo1 binding IREs (5'-CAAAACAAAACA-3') in the proximal *SCN5a* promoter region following immunoprecipitation with Foxo1 antibody, but not with IgG control (Fig. 1B). Another pair of primers was designed to amplify a region away from Foxo1 binding site, 5'-CAAAACA-3'. As showed in Figure S1, there was no PCR product detected after chromatin immunoprecipitation by Foxo1 antibody.

### Foxo1 Negatively Regulates *SCN5a* Promoter Activity

This conserved sequence is located from −1484 to −1473 in the mouse *SCN5a* promoter region. The proximal promoter region (−2308 to +119 bp) was examined in luciferase reporter assays in HeLa cells with and without expression of Foxo1 (Fig. 2A). Expression of Foxo1 significantly suppressed *SCN5a* promoter activity ( $p < 0.01$ ), and the suppression was Foxo1 dose dependent (Fig. 2B). Individual (CAAAAC to CCCAAC) or double mutations (CAAAACAAAACA to CCCAACCCAACA) in Foxo1 binding






**Figure 1. Foxo1 directly binds the insulin response elements in *SCN5a* promoter region.** A. Analysis of proximal region of the *SCN5a* promoter showed two overlapping conservative Foxo binding insulin response elements, 5'-CAAACA-3', in rat, mouse and human. B. ChIP assay showed that Foxo1 bound *SCN5a* promoter region in both HL-1 cells (upper panel) and adult mouse ventricular myocytes (lower panel) using two sets of paired primers, respectively. Lane 1 and 2 were input and IgG, respectively. doi:10.1371/journal.pone.0032738.g001


sites significantly suppressed ( $p < 0.01$ ) Foxo1 responsiveness compared with wild type *SCN5a*, and double mutations of Foxo1 were significantly more effective ( $p < 0.05$ ) than mutation 1 on *SCN5a* promoter activity (Fig. 2C).

**Foxo1 Negatively Regulates Nav1.5 Expression in HL-cells**

HL-1 cells harbor robust, rapidly activated and inactivated  $Na^+$  currents [39], indicating that  $Na_v1.5$  is expressed in HL-1 cells. In order to test the hypothesis that Foxo1 regulates  $Na_v1.5$  expression, HL-1 cells were used in the study. The HL-1 cells were infected for 48 hours by 10 or 50 multiplicity of infection (MOI) adenoviruses (Adv)-CMV-Foxo1-AA-GFP [40] and 50 MOI Adv-CMV-GFP. Western blot analysis of the protein extracts from these infected HL-1 cells was performed, and showed that  $Na_v1.5$  protein was more significantly decreased ( $p < 0.05$  or  $p < 0.01$ ) in cells expressing constitutively nuclear Foxo1-AA-GFP (AA: T24A/S319A) compared to cells expressing GFP (Fig. 3A and C). Interestingly, endogenous Foxo1 was significantly increased by overexpression of Foxo1-AA-GFP (Fig. 3A). This finding is consistent with a previous report that Foxo1 can be positively regulated by Foxo1 binding its own promoter [41]. Accordingly,  $Na_v1.5$  mRNA level determined by semi-quantitative RT-PCR analysis was also significantly decreased ( $p < 0.01$ ) in HL-1 cells expressing Foxo1-AA-GFP compared to HL-cells expressing GFP (Fig. 3B and D). This pair of primers (m1 $Na_v1.5$ ) for RT-PCR application was designed to detect two splicing variants,  $Na_v1.5a$  and  $Na_v1.5b$  [42]. In order to determine if Foxo1 affects the expression of these two splicing variants, the second pair of primers (m2 $Na_v1.5$ ) was designed to allow us to detect  $Na_v1.5$ ,  $Na_v1.5a$  and  $Na_v1.5b$ . Unfortunately, there was only one band of PCR product at 1300 bp detected, which consistently showed the inhibition of  $Na_v1.5$  expression by Foxo1-AA-GFP in HL-1 cells (Figure S2). This has prevented us from addressing if Foxo1 also affects the expression of other splicing variant(s).



**Figure 2. Foxo1 decreases *SCN5a* promoter activity.** A. Luciferase constructs contain proximal region of *SCN5a* promoter which has Foxo1 binding insulin response elements and mutations. B. Foxo1 significantly suppressed *SCN5a* promoter activity with dose dependence (\*\* $p < 0.01$ ,  $n = 3$ ). C. Individual or double mutations of Foxo1 binding sites in *SCN5a* promoter region prevented Foxo1 inhibition (\*\* $p < 0.01$ ) compared with wild type *SCN5a*; Double mutation of Foxo1 binding sites had significantly more effective ( $\#p < 0.05$ ) than mutation 1 ( $n = 6$  in all individual groups). doi:10.1371/journal.pone.0032738.g002



**Figure 3. Constitutively nuclear Foxo1 reduced Nav<sub>v</sub>1.5 expression.** Western blots showed that overexpression of Foxo1-AA-GFP for 36 hours reduced Nav<sub>v</sub>1.5 protein level while it increased endogenous Foxo1 expression (A); quantitation of Nav<sub>v</sub>1.5 protein level relative to GAPDH revealed that expression of Foxo1-AA-GFP (n = 5) significantly decreased (\*p < 0.05, at 10 MOI; \*\*p < 0.01 at 50 MOI) Nav<sub>v</sub>1.5 expression compared with 50 MOI GFP (n = 5) (C). RT-PCR showed that overexpression of 50 MOI Foxo1-AA-GFP for 36 hours decreased Nav<sub>v</sub>1.5 mRNA level compared with that in cells expressing 50 MOI GFP (B) and the values of Nav<sub>v</sub>1.5 mRNA relative to β-actin between GFP (n = 4) and Foxo1-AA-GFP (n = 4) groups were significantly different (\*\*p < 0.01) (D). doi:10.1371/journal.pone.0032738.g003

As shown above, robust Nav<sub>v</sub>1.5 expression was observed in the HL-1 cells (Fig. 3A and B). To test the hypothesis that a decrease of endogenous Foxo1 expression upregulates Nav<sub>v</sub>1.5 expression, Adv-FoxO1-RNAi was used to infect HL-1 cells to express RNAi and silence Foxo1 expression (Fig. 4A). The downregulation of Foxo1 induced a significant increase in both Nav<sub>v</sub>1.5 protein (p < 0.05, at 100 MOI) (4A and C) and mRNA levels (p < 0.01, at 100 MOI) in HL-1 cells (4B and D) when compared with those obtained from the cells infected with Adv-scramble-RNAi. This FoxO1-RNAi construct encodes a 19-bp oligonucleotide (5'-CGCCCCAGGTGGTGGAGAC-3') that is complementary to the mouse Foxo1 mRNA sequence (10–29 nt). This sequence has two nucleotides different from that of human Foxo1 mRNA and one nucleotide at the most 5' different from that of TR4 mRNA encoded by *Nrc2c* gene. In order to determine the specificity of this RNAi, human HeLa cells expressing endogenous Foxo1 [43] and HL-1 cells were infected with Adv-Foxo-RNAi and Adv-scramble-RNAi, respectively. RT-PCR analysis showed that Foxo1 mRNA in HeLa cells and TR4 mRNA in HL-1 cells were not altered by expression of Adv-Foxo1-RNAi (Figure S3 and S4), indicating that RNAi specifically targeted mouse Foxo1 mRNA.

#### Foxo1 Nuclear Localization Reduces Na<sup>+</sup> Currents in HL-1 cells

To test the hypothesis that activation of Foxo1 reducing Nav<sub>v</sub>1.5 expression decreases functional Na<sup>+</sup> currents, whole-cell voltage-clamp Na<sup>+</sup> current recordings were performed on HL-1 cells


infected with 50 MOI Adv-CMV-GFP and 50 MOI Adv-CMV-Foxo1-AA-GFP for 48 hours, respectively. Foxo1-AA-GFP was localized in the nuclei (Fig. 5B), while GFP was seen in both cytoplasm and nuclei (Fig. 5A). Recording traces of rapidly activating and inactivating Na<sup>+</sup> currents from GFP and Foxo1-AA-GFP-expressing cells, respectively, 36 hours after adenovirus infection, are illustrated in Figure 5C and D. Na<sup>+</sup> currents were significantly inhibited by expression of Foxo1-AA-GFP, and peak Na<sup>+</sup> current density was significantly lower (p < 0.01) in cells expressing Foxo1-AA-GFP (19.6 ± 5.6 pA/pF, at -25 mV) than in cells expressing GFP (67.9 ± 9.6 pA/pF, at -25 mV).

#### H<sub>2</sub>O<sub>2</sub> Promoting Foxo1 Nuclear Localization Reduces Nav<sub>v</sub>1.5 Expression


**H<sub>2</sub>O<sub>2</sub> Promotes Foxo1 nuclear localization:** HL-1 cells were infected with 50 MOI Adv-CMV-Foxo1-GFP and 50 MOI Adv-CMV-GFP. These infected cells were cultured for 36 hours. Fifty μM H<sub>2</sub>O<sub>2</sub> was then added to the culture medium. Fluorescent and confocal images showed that 2 hours of treatment with H<sub>2</sub>O<sub>2</sub> promoted Foxo1-GFP to localize in nuclei, but not GFP (Fig. 6).

**H<sub>2</sub>O<sub>2</sub> inhibiting Nav<sub>v</sub>1.5 expression is through the Foxo1 signaling pathway:** Increase of Foxo1 nuclear localization by H<sub>2</sub>O<sub>2</sub> is expected to reduce Nav<sub>v</sub>1.5 expression. In order to confirm this assumption, RNA and protein were extracted from HL-1 cells treated with 25 μM H<sub>2</sub>O<sub>2</sub> for 48 hours. Analyses of RT-PCR products and Western blot results showed that both Nav<sub>v</sub>1.5 protein and mRNA levels were significantly decreased (p < 0.05)






**Figure 4. Silencing expression of Foxo1 increases Na<sub>v</sub>1.5 expression.** Western blots showed decrease of Foxo1 protein by 50 MOI (n = 4) and 100 MOI Adv-Foxo1 RNAi (n = 4) increased Na<sub>v</sub>1.5 protein in HL-1 cells in comparison with 100 MOI Adv-scramble RNAi (n = 4) (A) and this inhibition reached the significant difference (\*p < 0.05) at 100 MOI Adv-Foxo1-RNAi (C). RT-PCR showed that Na<sub>v</sub>1.5 mRNA was increased by 50 MOI Foxo1-RNAi (n = 4) in comparison with that in cells expression scramble RNAi (n = 4) (B). The values of Na<sub>v</sub>1.5 mRNA relative β-actin between Foxo1-RNAi and scramble RNAi groups were significant different (\*\*p < 0.05) (D). doi:10.1371/journal.pone.0032738.g004



**Figure 5. Foxo1 inhibits Na<sup>+</sup> channel activity.** Foxo1-AA-GFP was localized in HL-1 cardiomyocyte nuclei (B) while GFP was seen in both nuclei and cytoplasm (A). Whole cell Na<sup>+</sup> currents were recorded during 80 ms depolarizing voltage steps to potentials between -60 and +60 mV from a holding potential of -100 mV in HL-1 cells expressing GFP or Foxo1-AA-GFP for 36 hours. The typical whole cell recording traces showed that robust Na<sup>+</sup> currents were present in HL-1 cells expressing GFP (C) while remarkable reduction of Na<sup>+</sup> currents in these cells expressing Foxo1-AA-GFP (D). doi:10.1371/journal.pone.0032738.g005



**Figure 6. H<sub>2</sub>O<sub>2</sub> promotes Foxo1 nuclear localization.** HL-1 cells were treated with 50 MOI Adv-CMV-GFP or 50 MOI Adv-CMV-Foxo1-GFP for 36 hours and then, 50 μM H<sub>2</sub>O<sub>2</sub> was added in the medium. GFP was expressed in both cytoplasm and nuclei and its localization was not altered by 2 hour H<sub>2</sub>O<sub>2</sub> treatment (A) while Foxo1-GFP was expressed in the cytoplasm and 2 hour H<sub>2</sub>O<sub>2</sub> treatment promoted Foxo1-GFP nuclear localization (B). All images were taken with lx81 fluorescence confocal microscopy.

doi:10.1371/journal.pone.0032738.g006

(Fig. 7A, C and B, D) in comparison with controls. In order to determine if H<sub>2</sub>O<sub>2</sub> reducing Nav<sub>v</sub>1.5 expression was through the Foxo1 signaling, 100 MOI Adv-scramble RNAi and 100 MOI Adv-Foxo1-RNAi were used to infect HL-1 cells and 25 μM H<sub>2</sub>O<sub>2</sub> was added in the culture medium after the cells expressed scramble RNAi and Foxo1-RNAi for 24 hours. Both Nav<sub>v</sub>1.5 mRNA and protein levels were significantly increased ( $p < 0.05$  and  $p < 0.01$ , respectively) in the cells expressing Foxo1 RNAi with a 48-hour H<sub>2</sub>O<sub>2</sub> treatment when compared with the cells expressing scramble RNAi with 48 hour H<sub>2</sub>O<sub>2</sub> treatment (Fig. 8A, C and B, D).

## Discussion

### Foxo1 negatively regulates Nav<sub>v</sub>1.5 expression

Foxo1 is known to function primarily as a transcription factor. The results presented here demonstrate that Foxo1 directly binds the IRE in the *SCN5a* promoter region and inhibits its promoter activity. This inhibition leads to downregulation of Nav<sub>v</sub>1.5 expression and a decrease of cardiac Na<sup>+</sup> channel activity. In the nucleus, Foxo proteins bind a conserved DNA binding sequence, 5'-GTAAA(C/T)A-3' [30] or IRE, 5'-CAAAA(C/T)A-3' [30–32] in the promoter regions of the targeted genes. Foxo


recruitment to the promoter regions usually positively regulates expression of the target genes. For example, Foxo1 bound the consensus sequence in the Kir 6.1 gene promoter and increased the expression of KATP subunit Kir6.1 [25]. In the literature, there is one report in which the authors identified Foxo1 as a corepressor for androgen receptor (AR) [44]. Some corepressors possess intrinsic histone deacetylases (HDAC) activity and some repress gene expression through recruitment of HDAC proteins [45]. It has been shown that HDAC3, but not HDAC1 and HDAC2 associate with Foxo1, enhancing Foxo1-induced inhibition of AR function in LNCaP cells [46]. Whether Foxo1 recruits HDAC3 to inhibit the *SCN5a* promoter activity remains undetermined.

### H<sub>2</sub>O<sub>2</sub> suppressing Nav<sub>v</sub>1.5 expression requires Foxo1


ROS have been shown to acutely enhance late Na<sup>+</sup> currents, leading to action potential prolongation and early afterdepolarizations [47–49] via activating CamKII [8,7] and phosphorylating Nav<sub>v</sub>1.5. ROS have also been reported to acutely reduce fast transient outward K<sup>+</sup> current, leading to the prolongation of cardiac repolarization by phosphorylating Kv4.3 [50]. The chronic effects of H<sub>2</sub>O<sub>2</sub> on Nav<sub>v</sub>1.5 expression were also well studied [9]. Nav<sub>v</sub>1.5 expression was suppressed by H<sub>2</sub>O<sub>2</sub> activating NF-KappaB and partially inhibiting *SCN5a* promoter activity [9]. These findings indicate that other mechanisms are also involved in the regulation of Nav<sub>v</sub>1.5 expression at the transcriptional level. As reflected in our studies, H<sub>2</sub>O<sub>2</sub> reduced Nav<sub>v</sub>1.5 expression by promoting Foxo1 nuclear localization, and Foxo1 signaling is required for H<sub>2</sub>O<sub>2</sub> to affect Nav<sub>v</sub>1.5 expression. ROS modulate Foxo1 subcellular localization through different pathways. H<sub>2</sub>O<sub>2</sub> inhibits phosphorylation of Foxo1 at Ser-253 and Thr-24 by reducing Akt kinase activity in response to insulin [12]. Under oxidative stress, the activated JNK pathway decreases the activity of Akt in HIT cells, leading to the decrease of phosphorylation of Foxo1 and promoting its nuclear localization [51]. Oxidative stress also augments PRMT1-induced Foxo1 methylation, thereby leading to the inhibition of its phosphorylation by Akt and promotion of its nuclear localization [13]. Sirt1 has been reported to be activated by H<sub>2</sub>O<sub>2</sub> and the subsequently activated Sirt1 deacetylates and entraps Foxo1 in the nucleus, which is also independent of H<sub>2</sub>O<sub>2</sub>-induced dephosphorylation of Foxo1 [12]. It is likely that Sirt1, Akt, JNK and PRMT1 signaling pathways are involved in the regulation of Nav<sub>v</sub>1.5 expression under oxidative stress. Foxo4 has been shown to interact with NF-KappaB and subsequently inhibit its transcriptional activity [52]. Whether Foxo1 suppressing Nav<sub>v</sub>1.5 expression in cardiac myocytes is also partially through the NF-KappaB signaling pathway remains to be verified.

### Novelty and Potential Significance

ROS including H<sub>2</sub>O<sub>2</sub> are significantly elevated in ischemic heart disease (IHD), [1–4] in which arrhythmias are frequently observed. A significant decrease in Na<sup>+</sup> channel activity is considered to be one of mechanisms contributing to the development of arrhythmias in IHD [5,6]. The mechanisms of transcriptional regulation of Nav<sub>v</sub>1.5 expression are largely uncertain. In this study, we demonstrated that Foxo1 directly targeted the *SCN5a* promoter and inhibited its transcriptional activity. Furthermore, we confirmed that H<sub>2</sub>O<sub>2</sub> promoted Foxo1 nuclear translocation. This Foxo1 relocation is required for H<sub>2</sub>O<sub>2</sub>-mediated Nav<sub>v</sub>1.5 downregulation. These findings indicate the important role of Foxo1 in cardiac ion channel regulation and in the development of arrhythmias.



**Figure 7. H<sub>2</sub>O<sub>2</sub> reduces Nav1.5 expression.** Western blot analysis showed that Nav1.5 protein was significantly decreased (\*p<0.05) in HL-1 cells treated with 25 μM H<sub>2</sub>O<sub>2</sub> for 48 h hours (n=3) compared with the control group (n=3) (A, C). RT-PCR analysis showed that Nav1.5 mRNA significantly reduced (p\*<0.05) in HL-1 cells treated with 25 μM H<sub>2</sub>O<sub>2</sub> for 48 hours (n=3) compared with the control group (n=4) (B, D). doi:10.1371/journal.pone.0032738.g007



**Figure 8. H<sub>2</sub>O<sub>2</sub>-mediated downregulation of Nav1.5 requires Foxo1.** Western blot analysis showed that Nav1.5 protein was significantly increased (\*p<0.05) in HL-1 cells cultured in the medium with 25 μM H<sub>2</sub>O<sub>2</sub> treatment for 48 hours after the cells expressed Foxo1-RNAi for 24 hours (n=4) compared with scramble RNAi group (n=4) (A, C). RT-PCR analysis showed that Nav1.5 significantly increased (\*\*p<0.01) in HL-1 cells in the medium with 25 μM H<sub>2</sub>O<sub>2</sub> treatment for 48 hours after the cells expressed Foxo1-RNAi for 24 hours (n=4) compared with scramble RNAi group (n=4) (B, D). doi:10.1371/journal.pone.0032738.g008



## Supporting Information

**Figure S1** Foxo1 does not bind the *SCN5a* promoter region lacking the insulin responsive element. A pair of primers was designed to amplify a region far away from Foxo1 binding site, 5'-CAAACA-3'. There was no PCR product detected after chromatin immunoprecipitation (ChIP) by Foxo1 antibody (Lane 3). Lane 1 and 2 were input DNA and control IgG ChIP, respectively. (TIF)

**Figure S2** One isoform of Nav1.5 is detected in HL-1 cells. RT-PCR using a pair of m2Nav1.5 primers showed that there was only one DNA band representative of Nav1.5 mRNA after 40 cycles. Overexpression of 50 MOI Foxo1-AA-GFP for 36 hours decreased Nav1.5 mRNA level compared with that in cells expressing 50 MOI GFP and the amount of sample loading was equal as determined by GAPDH RT-PCR products. (TIF)

**Figure S3** RNAi targeting mouse Foxo1 mRNA does not affect human Foxo1 expression. RT-PCR using a pair of hFoxo1 primers showed that human Foxo1 mRNA expression was not altered in the HeLa cells infected with 50 MOI Adv-Foxo1-RNAi

(n = 3) in comparison with the cells infected 50 MOI Adv-scramble-RNAi (n = 3) (A and B). (TIF)

**Figure S4** RNAi targeting mouse Foxo1 mRNA does not affect TR4 mRNA expression. RT-PCR using a pair of TR4 primers showed that TR4 mRNA expression was not altered in the HL-1 cells infected with Adv-Foxo1-RNAi (n = 3) in comparison with the cells infected Adv-scramble-RNAi (n = 3) (A and B). (TIF)

## Acknowledgments

We are grateful to Drs. William C. Claycomb and Hideko Kasahara for kindly providing HL-1 cells and *SCN5a* promoter-Luc plasmid, respectively.

Parts of this study were presented at the American Heart Association Scientific Sessions, Chicago, IL, 13–17 November, 2010 and Orlando, FL, 12–16 November, 2011.

## Author Contributions

Conceived and designed the experiments: HX FL WM TY. Performed the experiments: WM TY BY XL HX. Analyzed the data: WM TY HX. Contributed reagents/materials/analysis tools: HHD JAH. Wrote the paper: WM TY FL HX.

## References

- Zweier JL, Flaherty JT, Weisfeldt ML (1987) Direct measurement of free radical generation following reperfusion of ischemic myocardium. *Proc Natl Acad Sci U S A* 84: 1404–1407.
- Slezak J, Tribulova N, Pristacova J, Uhrík B, Thomas T, et al. (1995) Hydrogen peroxide changes in ischemic and reperfused heart. *Cytochemistry and biochemical and X-ray microanalysis*. *Am J Pathol* 147: 772–781.
- Lakatta EG, Sollott SJ (2002) The “heartbreak” of older age. *Mol Interv* 2: 431–446.
- Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y (2009) Reactive oxygen species promote angiogenesis in the infarcted rat heart. *Int J Exp Pathol* 90: 621–629.
- Pu J, Boyden PA (1997) Alterations of Na<sup>+</sup> currents in myocytes from epicardial border zone of the infarcted heart. A possible ionic mechanism for reduced excitability and postrepolarization refractoriness. *Circ Res* 81: 110–119.
- Baba S, Dun W, Cabo C, Boyden PA (2005) Remodeling in cells from different regions of the reentrant circuit during ventricular tachycardia. *Circulation* 112: 2386–2396.
- Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, et al. (2011) Reactive oxygen species-activated Ca/calmodulin kinase II $\delta$  is required for late I(Na) augmentation leading to cellular Na and Ca overload. *Circ Res* 108: 555–565.
- Xie LH, Chen F, Karagueuzian HS, Weiss JN (2009) Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. *Circ Res* 104: 79–86.
- Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, et al. (2008) NF- $\kappa$ B-dependent transcriptional regulation of the cardiac *scn5a* sodium channel by angiotensin II. *Am J Physiol Cell Physiol* 294: C372–379.
- Kaestner KH, Knochel W, Martinez DE (2000) Unified nomenclature for the winged helix/forkhead transcription factors. *Genes Dev* 14: 142–146.
- Ronnebaum SM, Patterson C The FoxO family in cardiac function and dysfunction. *Annu Rev Physiol* 72: 81–94.
- Qiang L, Banks AS, Accilli D (2010) Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. *J Biol Chem* 285: 27396–27401.
- Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, et al. (2008) Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. *Mol Cell* 32: 221–231.
- Brownawell AM, Kops GJ, Macara IG, Burgering BM (2001) Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. *Mol Cell Biol* 21: 3534–3546.
- Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, et al. (2002) 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. *J Cell Biol* 156: 817–828.
- Brunet A, Park J, Tran H, Hu LS, Hemmings BA, et al. (2001) Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHL1 (FOXO3a). *Mol Cell Biol* 21: 952–965.
- Huang H, Regan KM, Lou Z, Chen J, Tindall DJ (2006) CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. *Science* 314: 294–297.
- Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, et al. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. *Cell* 117: 225–237.
- Essers MA, Weijnen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, et al. (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. *Embo J* 23: 4802–4812.
- Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, et al. (2006) A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. *Cell* 125: 987–1001.
- Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, et al. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 419: 316–321.
- Sengupta A, Molkenin JD, Paik JH, Depinho RA, Yutzey KE (2011) FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. *J Biol Chem* 286: 7468–7478.
- Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, et al. (2010) Silent information regulator 1 protects the heart from ischemia/reperfusion. *Circulation* 122: 2170–2182.
- Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, et al. (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 $\alpha$  interaction. *Nature* 423: 550–555.
- Philip-Couderc P, Tavares NI, Roatti A, Lerch R, Montessuit C, et al. (2008) Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. *Circ Res* 102: e20–35.
- Sengupta A, Molkenin JD, Yutzey KE (2009) FoxO transcription factors promote autophagy in cardiomyocytes. *J Biol Chem* 284: 28319–28331.
- Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 404: 782–787.
- Evans-Anderson HJ, Alfieri CM, Yutzey KE (2008) Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors. *Circ Res* 102: 686–694.
- Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffier PJ, et al. (2002) The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. *J Immunol* 168: 5024–5031.
- Furuyama T, Nakazawa T, Nakano I, Mori N (2000) Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. *Biochem J* 349: 629–634.
- Cichy SB, Uddin S, Danilkovich A, Guo S, Klippel A, et al. (1998) Protein kinase B/Akt mediates effects of insulin on hepatic insulin-like growth factor-binding protein-1 gene expression through a conserved insulin response sequence. *J Biol Chem* 273: 6482–6487.
- Ayala JE, Streper RS, Desgrosellier JS, Durham SK, Suwanichkul A, et al. (1999) Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. *Diabetes* 48: 1885–1889.
- Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, et al. (2007) FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. *Cell* 128: 309–323.
- Xia M, Salata JJ, Figueroa DJ, Lawlor AM, Liang HA, et al. (2004) Functional expression of L- and T-type Ca<sup>2+</sup> channels in murine HL-1 cells. *J Mol Cell Cardiol* 36: 111–119.

35. Xu H, Guo W, Nerbonne JM (1999) Four kinetically distinct depolarization-activated K<sup>+</sup> currents in adult mouse ventricular myocytes. *J Gen Physiol* 113: 661–678.
36. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. *Genome Res* 12: 996–1006.
37. Briggs LE, Takeda M, Cuadra AE, Wakimoto H, Marks MH, et al. (2008) Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects. *Circ Res* 103: 580–590.
38. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, et al. (2004) Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. *J Clin Invest* 114: 1493–1503.
39. Nakajima T, Davies SS, Matafonova E, Potet F, Amarnath V, et al. (2010) Selective gamma-ketoaldehyde scavengers protect Nav1.5 from oxidant-induced inactivation. *J Mol Cell Cardiol* 48: 352–359.
40. Ni YG, Berenji K, Wang N, Oh M, Sachan N, et al. (2006) Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. *Circulation* 114: 1159–1168.
41. Essaghir A, Dif N, Marbehan CY, Coffey PJ, Demoulin JB (2009) The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. *J Biol Chem* 284: 10334–10342.
42. Zimmer T, Bollensdorff C, Haufe V, Birch-Hirschfeld E, Benndorf K (2002) Mouse heart Na<sup>+</sup> channels: primary structure and function of two isoforms and alternatively spliced variants. *Am J Physiol Heart Circ Physiol* 282: H1007–1017.
43. Zhao Y, Yang J, Liao W, Liu X, Zhang H, et al. (2010) Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. *Nat Cell Biol* 12: 665–675.
44. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, et al. (2007) Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. *J Biol Chem* 282: 7329–7338.
45. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. *Endocr Rev* 28: 778–808.
46. Liu P, Li S, Gan L, Kao TP, Huang H (2008) A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. *Cancer Res* 68: 10290–10299.
47. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L (2006) Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. *J Pharmacol Exp Ther* 318: 214–222.
48. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupersmidt S, et al. (2005) Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. *Circ Res* 97: 1262–1269.
49. Barrington PL, Meier CF, Jr., Weglicki WB (1988) Abnormal electrical activity induced by free radical generating systems in isolated cardiocytes. *J Mol Cell Cardiol* 20: 1163–1178.
50. Lu Z, Abe J, Taunton J, Lu Y, Shishido T, et al. (2008) Reactive oxygen species-induced activation of p90 ribosomal S6 kinase prolongs cardiac repolarization through inhibiting outward K<sup>+</sup> channel activity. *Circ Res* 103: 269–278.
51. Kawamori D, Kaneto H, Nakatani Y, Matsuoka TA, Matsuhisa M, et al. (2006) The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. *J Biol Chem* 281: 1091–1098.
52. Zhou W, Cao Q, Peng Y, Zhang QJ, Castrillon DH, et al. (2009) FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. *Gastroenterology* 137: 1403–1414.